FBRX - CIK 0001419041
Forte Biosciences, Inc. trades as FBRX. This page tracks Forte Biosciences, Inc. through 595 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -68322.4% to -11302.8% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Major company event | 8-K | 2026-05-14 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| SCHEDULE 13G | - | 2026-05-13 |
The largest companies sharing Forte Biosciences, Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Forte Biosciences, Inc. reported a net loss of $69.38M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.